Baar (Switzerland), Osaka (Japan), Tokyo (Japan), July 3, 2025 –

巴尔（瑞士），大阪（日本），东京（日本），2025年7月3日——

Stallergenes Greer, Shionogi & Co., Ltd. (“Shionogi”) and CEOLIA Pharma Co. Ltd (“CEOLIA”) today announced the transition of promotional activities for Actair® in Japan. Actair® is Stallergenes Greer’s sublingual immunotherapy tablet for the treatment of patients suffering from house dust mite induced allergic rhinitis..

Stallergenes Greer、盐野义制药株式会社（“Shionogi”）和CEOLIA Pharma Co. Ltd（“CEOLIA”）今天宣布了在日本的Actair®推广活动的过渡。Actair®是Stallergenes Greer的舌下免疫治疗片，用于治疗因尘螨引起的过敏性鼻炎患者。

After ending the license agreement established in 2010 with Shionogi, which had been responsible for developing, registering, and commercialising Actair® in Japan, Stallergenes Greer has appointed CEOLIA as its new promotional partner in the country starting July 3. To ensure the continuity of both patient care and support for healthcare professionals, Shionogi will continue during a transition period to serve as the Marketing Authorisation Holder (MAH) in Japan and remain responsible for the importation, manufacturing and distribution of Actair®.

在终止与盐野义制药于2010年签订的许可协议后——该协议曾负责在日本开发、注册和商业化Actair®——Stallergenes Greer自7月3日起任命CEOLIA作为其在日本的新推广合作伙伴。为确保患者护理及对医疗专业人士支持的连续性，盐野义制药将在过渡期内继续担任日本的上市许可持有人（MAH），并负责Actair®的进口、生产和分销。

Shionogi will also provide active support to CEOLIA by transferring knowledge and offering operational assistance..

盐野义制药还将通过转让知识和提供业务协助，为CEOLIA提供积极支持。

Stallergenes Greer acknowledges Shionogi’s contribution and sustained commitment to improving allergy care in Japan. The company welcomes CEOLIA as a trusted new partner and looks forward to working closely together to further advance access to allergen immunotherapy treatments and continue to improve the quality of life of patients with respiratory allergies..

斯托拉吉尼斯·格里尔公司认可盐野义制药在改善日本过敏症护理方面的贡献和持续承诺。该公司欢迎CEOLIA作为值得信赖的新合作伙伴，并期待紧密合作，进一步推动过敏原免疫治疗的可及性，继续改善呼吸道过敏患者的生存质量。

ABOUT STALLERGENES GREER

关于STALLERGENES GREER

Headquartered in Baar (Switzerland), Stallergenes Greer is a global healthcare company specialising in the diagnosis and treatment of allergies through the development and commercialisation of allergen immunotherapy products and services. Supported by more than 100 years of expertise and innovation, our products are available for patients in over 40 countries..

总部位于瑞士巴尔的 Stallergenes Greer 是一家全球性医疗保健公司，专注于通过开发和商业化过敏原免疫治疗产品和服务来诊断和治疗过敏。凭借 100 多年的专业知识和创新，我们的产品已在 40 多个国家和地区为患者提供服务。

For more information, visit

欲了解更多信息，请访问

www.stallergenesgreer.com.

www.stallergenesgreer.com.

ABOUT SHIONOGI & Co. Ltd

关于盐野义制药有限公司

Shionogi has identified “Contributing to a Healthy and Prosperous Life” as one of its key material issues. The group is committed to building a society where everyone can live vibrantly and true to themselves. With a continued focus on areas of high unmet medical needs, Shionogi strives to deliver innovative treatments that improve the quality of life (QOL) for patients and their families..

盐野义制药已将“为健康繁荣的生活做贡献”确定为其关键的实质性问题之一。该集团致力于构建一个让每个人都能充满活力、忠于自我生活的社会。盐野义持续专注于未被满足医疗需求的领域，努力提供创新疗法以改善患者及其家人的生活质量 (QOL)。

For more information, visit

欲了解更多信息，请访问

https://www.shionogi.com/jp/ja/

https://www.shionogi.com/jp/ja/

ABOUT CEOLIA

关于CEOLIA

CEOLIA, founded in 2010, is a pharmaceutical company dedicated to serving all healthcare needs in the otolaryngology (ENT) field. With a mission and philosophy to serve and contribute to people's health and happiness, we develop, manufacture and market ethical drugs, medical devices, and diagnostic reagents in the ENT field..

CEOLIA成立于2010年，是一家致力于满足耳鼻喉科（ENT）领域所有医疗需求的制药公司。秉承服务和促进人类健康与幸福的使命与理念，我们开发、生产和销售耳鼻喉科领域的伦理药物、医疗器械和诊断试剂。

For more information,

更多信息，请参阅

visit https://www.ceolia.co.jp/.

访问 https://www.ceolia.co.jp/。